
EquitySector - HealthcareVery High Risk
Direct
NAV (31-Oct-26)
Returns (Since Inception)
Fund Size
₹5,870 Cr
Expense Ratio
1.01%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+17.84%
+13.44% (Cat Avg.)
3 Years
+24.80%
+21.70% (Cat Avg.)
5 Years
+19.22%
+14.76% (Cat Avg.)
10 Years
+14.72%
+14.19% (Cat Avg.)
Since Inception
+17.92%
— (Cat Avg.)
| Equity | ₹5,607.87 Cr | 95.53% |
| Others | ₹262.13 Cr | 4.47% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹653.98 Cr | 11.14% |
| Divi's Laboratories Ltd | Equity | ₹464.58 Cr | 7.91% |
| Treps | Cash - Repurchase Agreement | ₹377.01 Cr | 6.42% |
| Acutaas Chemicals Ltd | Equity | ₹295.15 Cr | 5.03% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹261.3 Cr | 4.45% |
| Torrent Pharmaceuticals Ltd | Equity | ₹259.2 Cr | 4.42% |
| Cipla Ltd | Equity | ₹258.43 Cr | 4.40% |
| Laurus Labs Ltd | Equity | ₹237.6 Cr | 4.05% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹223.15 Cr | 3.80% |
| Aurobindo Pharma Ltd | Equity | ₹200.64 Cr | 3.42% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹188.23 Cr | 3.21% |
| Gland Pharma Ltd | Equity | ₹173.96 Cr | 2.96% |
| Sudeep Pharma Ltd | Equity | ₹163.99 Cr | 2.79% |
| Anthem Biosciences Ltd | Equity | ₹161.42 Cr | 2.75% |
| Sai Life Sciences Ltd | Equity | ₹152.45 Cr | 2.60% |
| Corona Remedies Ltd | Equity | ₹142.35 Cr | 2.43% |
| Biocon Ltd | Equity | ₹138.86 Cr | 2.37% |
| Fortis Healthcare Ltd | Equity | ₹138.6 Cr | 2.36% |
| Concord Biotech Ltd | Equity | ₹131.87 Cr | 2.25% |
| Aether Industries Ltd | Equity | ₹127.45 Cr | 2.17% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹126.8 Cr | 2.16% |
| Net Receivable / Payable | Cash - Collateral | ₹-117.86 Cr | 2.01% |
| Poly Medicure Ltd | Equity | ₹107.12 Cr | 1.82% |
| Ajanta Pharma Ltd | Equity | ₹104.93 Cr | 1.79% |
| Global Health Ltd | Equity | ₹102.38 Cr | 1.74% |
| Mankind Pharma Ltd | Equity | ₹100.15 Cr | 1.71% |
| HealthCare Global Enterprises Ltd | Equity | ₹99.91 Cr | 1.70% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹99.36 Cr | 1.69% |
| Cohance Lifesciences Ltd | Equity | ₹97.68 Cr | 1.66% |
| Innova Captab Ltd | Equity | ₹96.64 Cr | 1.65% |
| Dr. Lal PathLabs Ltd | Equity | ₹95.38 Cr | 1.62% |
| Nephrocare Health Services Ltd | Equity | ₹65.97 Cr | 1.12% |
| Syngene International Ltd | Equity | ₹65.75 Cr | 1.12% |
| Rainbow Childrens Medicare Ltd | Equity | ₹39.43 Cr | 0.67% |
| Gufic Biosciences Ltd | Equity | ₹17.28 Cr | 0.29% |
| Abbott India Ltd | Equity | ₹13.56 Cr | 0.23% |
| Day Tbill | Bond - Gov't/Treasury | ₹2.98 Cr | 0.05% |
| Evonile Pharma Ltd | Equity | ₹2.34 Cr | 0.04% |
Large Cap Stocks
32.33%
Mid Cap Stocks
25.68%
Small Cap Stocks
37.53%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹5,185.27 Cr | 88.34% |
| Basic Materials | ₹422.59 Cr | 7.20% |
Standard Deviation
This fund
14.38%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
1.20
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better
Since June 2011
ISIN INF200K01UP2 | Expense Ratio 1.01% | Exit Load No Charges | Fund Size ₹5,870 Cr | Age 13 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹12,90,879 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments